Ascendis Pharma A/S
Price Action
Technical Summary
STAGE 2 UPTRENDAscendis Pharma A/S is in a confirmed Stage 2 uptrend, with price holding above all major moving averages and trend structure remaining intact. Relative strength is leading (RS Rating: 81), indicating clear outperformance against the broad market. Earnings growth of 7% provides fundamental context to the price action. However, with RSI at 76, the stock is extended and may be prone to a short-term pullback.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $237.85 | +12.64% | ABOVE |
| 50 SMA | $234.60 | +14.20% | ABOVE |
| 100 SMA | $232.74 | +15.12% | ABOVE |
| 150 SMA | $226.37 | +18.36% | ABOVE |
| 200 SMA | $220.69 | +21.40% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is ASND in an uptrend right now?
ASND has a trend score of 4/4 based on Minervini's Stage Analysis. Yes, ASND is in a Stage 2 uptrend with price above all major moving averages (50, 100, 150, 200 SMA) properly stacked.
Is ASND overbought or oversold?
ASND's RSI (14) is 76. The stock is in overbought territory (RSI > 70), which may signal a pullback.
Is ASND outperforming the market?
ASND has a Relative Strength (RS) Rating of 81 out of 99. Yes, ASND is a market leader, outperforming 81% of all stocks over the past 12 months.
Where is ASND in its 52-week range?
ASND is trading at $267.92, which is 97% of its 52-week high ($274.89) and 94% above its 52-week low ($160.86).
How volatile is ASND?
ASND has a Beta of 0.32 and 52-week volatility of 38%. It's less volatile than the S&P 500 - generally more stable.